Study Comparing Weekly Taxol and Carboplatin vs Standard Taxol and Carboplatin Regimen for Stage IIIB or IV Non-Small-Cell Lung Cancer
Taxol and carboplatin are commonly used drugs for the treatment of stage IIIB or IV non small cell lung carcinoma.
This study compares treatment with Taxol/carboplatin given every 3 weeks to a schedule where it is given weekly.
The purpose of the study is to determine the most effective and safe schedule for giving these drugs in non small cell lung carcinoma.
Carcinoma, Non-Small-Cell Lung
Drug: Paclitaxel and carboplatin
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||A Multicenter, Randomized Trial for Stage IIIB or IV NSCLC Comparing Weekly Taxol(Paclitaxel) and Carboplatin(Paraplatin) Regimen Versus Standard Taxol and Carboplatin Administered Every Three Weeks, Followed by Weekly Taxol.|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00035152
Show 56 Study Locations